ESRD. End stage kidney disease on dialysis
Conditions
Interventions
Intervention 1: Pregabalin (Oral Capsule 50 mg): The initial dose of pregabalin is 50 mg three times a week (after each dialysis session in hemodialysis patients). After one week, if response to the m
Treatment - Drugs
Pregabalin (Oral Capsule 50 mg): The initial dose of pregabalin is 50 mg three times a week (after each dialysis session in hemodialysis patients). After one week, if response to the medication is not
Doxepin (Oral Capsule 10 mg): The initial dose of doxepin is 10 mg per day. After 1 week, if response to the medication is not satisfactory, dose of the drug will be increased to 10 mg two times per d
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 16-80 years old; undergoing regular hemodialysis or peritoneal dialysis Exclusion criteria: history of allergy to pregabalin or doxepin; liver failure; pregnancy; history of epilepsy or a single episode of seizure; uncontrolled psychiatric illness; decompensated heart failure; narrow angle glaucoma; hyperthyroidism; history of myocardial infarction in the past three months; heart block; low blood pressure(Systolic blood pressure less than 90 mmHg)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of pruritus. Timepoint: Before the intervention, and one week, two weeks and four weeks after the intervention. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of pruritus and its impact on the quality of life. Timepoint: Before the intervention, and one week, two weeks and four weeks after the intervention. Method of measurement: 5-D itch scale.;Effect of pruritus on the quality of life. Timepoint: Before the intervention and one week, two weeks and four weeks after the intervention. Method of measurement: Dermatology Life Quality Index (DLQI).;Adverse effects. Timepoint: At the end of the first and fourth weeks of the intervention. Method of measurement: Checklist of adverse effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaemeh Nikvarz
Kerman University of Medical Sciences
Outcome results
None listed